MIAS Pharma at SNMMI 2026
The 2026 SNMMI Annual Meeting will feature:
- Revolutionary research shaping the future of nuclear medicine and molecular imaging
- Advanced clinical applications transforming patient care
- Unparalleled networking opportunities with global thought leaders
Venue
Los Angeles Convention Center
Los Angeles, CA
May 30 – June 2, 2026
Your partner in quality, safety, and compliance
The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.
Related services
Related articles
07 Apr 2026
MIAS Pharma will be attending the BIO International Convention in San Diego, USA
MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.
20 Mar 2026
Labelling & Packaging: A Core MAH Responsibility
Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.
13 Mar 2026
Getting ready for product launch with serialisation
As your medicinal product moves from the clinical space into commercial launch territory, one crucial question looms large:
06 Mar 2026
MAHs: Are Your GMP–GVP Interfaces Aligned?
Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?
27 Feb 2026
MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies
For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.
20 Feb 2026
Quality & Regulatory Implications from EU Critical Medicines Act
The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.
28 Jan 2026
Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?
As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.